Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Y0001601

Alfacalcidol for system suitability

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

1α-Hydroxyvitamin D3, 1α-Hydroxycholecalciferol, Alfacalcidol

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C27H44O2
Numero CAS:
Peso molecolare:
400.64
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Origine biologica

synthetic

Grado

pharmaceutical primary standard

agenzia

EP

Stato

solid

Produttore/marchio commerciale

EDQM

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

pharmaceutical (small molecule)

Formato

neat

Temperatura di conservazione

−20°C

Stringa SMILE

CC(C)CCC[C@@H](C)[C@H]1CC[C@H]2\C(CCC[C@]12C)=C\C=C3\C[C@@H](O)C[C@H](O)C3=C

InChI

1S/C27H44O2/c1-18(2)8-6-9-19(3)24-13-14-25-21(10-7-15-27(24,25)5)11-12-22-16-23(28)17-26(29)20(22)4/h11-12,18-19,23-26,28-29H,4,6-10,13-17H2,1-3,5H3/b21-11+,22-12-/t19-,23-,24-,25+,26+,27-/m1/s1
OFHCOWSQAMBJIW-AVJTYSNKSA-N

Informazioni sul gene

human ... VDR(7421)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia.

Azioni biochim/fisiol

Synthetic vitamin D3 analog that is metabolized to 1,25-dihydroxycholecalciferol. Inhibits bone resorption and stimulates bone formation. Supresses parathyroid hormone secretion by bovine parathyroid cells.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Skull and crossbones

Avvertenze

Danger

Indicazioni di pericolo

Consigli di prudenza

Classi di pericolo

Acute Tox. 1 Oral

Codice della classe di stoccaggio

6.1B - Non-combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Vitamin D and metabolites measurement by tandem mass spectrometry
van den Ouweland JMW, et al.
Reviews in Endocrine & Metabolic Disorders, 14(2), 159-184 (2013)
Novel approach for the determination of alfacalcidol in bulk and tablet dosage form using spectrophotometric method
Saeed-Ul-Hassan S, et al.
Latin American Journal of Pharmacy, 32(5), 784-788 (2013)
Florent Richy et al.
Aging clinical and experimental research, 17(2), 133-142 (2005-06-28)
Alfacalcidol (1-alpha-hydroxyvitamin D3) is a non-endogenous analog of vitamin D which can bypass the renal and intestinal regulatory mechanisms that control the production of calcitriol (1,25-hydroxyvitamin D3, the active form of vitamin D, D-Hormone). Alfacalcidol may be metabolized into calcitriol
P Sambrook
Calcified tissue international, 65(4), 341-343 (1999-09-15)
There is increasing evidence that D-hormones (active vitamin D metabolites) are effective agents in preventing posttransplantation bone loss of various organs. This effect may relate to several mechanisms including reversal of secondary hyperparathyroidism from cyclosporine, reversal of corticosteroid effects on
J D Ringe et al.
Rheumatology international, 28(2), 103-111 (2007-08-02)
While in other chronic diseases combined treatment regimens are the rule there is a lack of reported experience or study data on combining different specific drugs to treat osteoporosis. Significant differences in the mode of action (MOA) of the substances

Domande

Recensioni

Nessuna valutazione

Filtri attivi

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.